ALTANA

ALTANA AG is an international pharmaceuticals and chemicals group with sales of EUR948 million in the first quarter of 2006 and approx. 13,400 employees all over the world. With a return on sales (EBT) of around 20%, ALTANA is one of the most profitable pharmaceuticals and chemicals companies in Europe.
The ALTANA Group is composed of the strategic management holding company, ALTANA AG, and two operating divisions, ALTANA Pharma AG and ALTANA Chemie AG. This structure enhances the flexibility of the individual divisions and enables targeted development.

ALTANA Pharma:
ALTANA Pharma AG, based in Constance, concentrates on innovative prescription therapeutics. Its core business comprises gastrointestinal, respiratory tract, and cardiovascular preparations. In its research, ALTANA Pharma focuses on gastrointestinal (gastroenterology), respiratory tracts (respiration/anti-inflammation), and cancer (oncology). Due to high research and development expenses, intelligent alliances, and the concentration on profitable markets, we have an outstanding position in global competition.

ALTANA Chemie:
ALTANA Chemie AG, headquartered in Wesel, has established itself as a global provider of innovative, environmentally compatible solutions and the corresponding special products for coatings manufacturers, coatings and plastics processors and the electronics industry. The product range includes additives, metallic effect pigments, specialty coatings, sealing and casting compounds, electrical insulation material, impregnating agents as well as testing and measuring instruments. With these products, ALTANA Chemie has been successful in selected niche markets worldwide. All four of its business units are among the leading manufacturers in their markets.

Contact Details: Am Pilgerrain 15 61352 Bad Homburg v. d. Höhe Germany Tel: +49 (0)6172/ 17 12 -0 Fax: +49 (0)6172/ 17 12 -365 Email: pr@altana.de WWW: www.altana.de/

Recent Publications by ALTANA:
A novel screening strategy to identify ABCB1 substrates and inhibitors. We tested the hypothesis whether data on ABCB1 ATPase activity and passive...	15th July, 2009	Division of Drug Metabolism and Pharmacokinetics, Altana Pharma AG,	Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26. Epub 2008 Aug DOI Direct Link
Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. OBJECTIVE: To investigate the effects of steady state erythromycin on the...	3rd June, 2009	Nycomed GmbH (formerly ALTANA Pharma AG), Konstanz, Germany.	Int J Clin Pharmacol Ther. 2009 Apr;47(4):236-45.
A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening. Most cellular assays that quantify the efficacy of histone deacetylase...	28th February, 2008	Therapeutic Area Oncology, ALTANA Pharma-a member of the Nycomed Group,	Anal Biochem. 2008 Jan 1;372(1):72-81. Epub 2007 Aug 2. DOI Direct Link
Systematic expression profiling of the gastric H+/K+ ATPase in human tissue. OBJECTIVE: The potassium-competitive acid blockers (P-CABs), comprise a...	25th January, 2008	Department of Biochemistry Gastroenterology, ALTANA Pharma AG, Konstanz,	Scand J Gastroenterol. 2007 Nov;42(11):1275-88. DOI Direct Link
Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drugs that interfere with the normal progression of mitosis belong to the...	4th January, 2008	Altana Pharma AG, Therapeutic Area Oncology, Byk-Gulden Strasse 2,	Drug Resist Updat. 2007 Aug-Oct;10(4-5):162-81. Epub 2007 Jul 31. DOI Direct Link
→View more ALTANA research publications.

Press Releases on ALTANA:
Reportlinker Adds Gastrointestinal Pharmaceuticals: Technologies and Markets	3rd November, 2009	Reportlinker	NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Gastrointestinal Pharmaceuticals: Technologies and Markets http://www
ALTANA Pharma obtains first license to atugen’s proprietary lipids	1st January, 1970	Atugen	ALTANA Pharma obtains first license to atugen’s proprietary lipids
CHI's Business Strategies and Alliance Management Congress - Early	1st January, 1970	Chi	REGISTER BY MARCH 5TH AND SAVE UP TO $200!!!

BioNews Results for ALTANA:
CONTRAST Published: Iodixanol Best Choice for High-Contrast Use Patients	TCTMD.com:  Oct 30 2009 12:57PM Matching: altana
SKion GmbH Makes a New, Improved Tender Offer for Acquisition of ALTANA Shares	Ink World:  Oct 26 2009 11:11PM Matching: altana
ALTANA Completes Acquisition of Water Ink Technologies	Ink World:  Oct 14 2009 5:20AM Matching: altana

ALTANA Clinical Trials:
Long-Term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)

ALTANA Patents:
US Patent No.	Title
6927292	Tricyclic epoxides
7041313	Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
7045174	Method and device for insulating electro-technical components
7053176	Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
7056936	Synergistic combination
→View more ALTANA patents.

ALTANA (AAA) Financial information Links from Barchart
AAA Quote from from Barchart.com
AAA Chart from from Barchart.com
AAA Profile from from Barchart.com
AAA Opinion from from Barchart.com
→View more ALTANA finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 12 individuals from ALTANA using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 250 times since April 2007, the link to the organisation's website has been followed 37 times

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for ALTANA